<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543370</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-1004-106</org_study_id>
    <nct_id>NCT04543370</nct_id>
  </id_info>
  <brief_title>Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate CYP3A4 Drug-Drug Interactions of Edasalonexent in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-drug interaction (DDI) and Cardiodynamic Evaluation Study To assess the effect of&#xD;
      multiple oral doses of edasalonexent on the single-dose pharmacokinetics (PK) of midazolam (a&#xD;
      cytochrome P450 [CYP]3A4 sensitive substrate) and of deflazacort (a CYP3A4 moderate sensitive&#xD;
      substrate) in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, fixed-sequence DDI and cardiodynamic study in healthy adult subjects.&#xD;
&#xD;
      Twenty-six (26), healthy, adult male and female (non-childbearing potential) subjects will be&#xD;
      enrolled.&#xD;
&#xD;
      Screening of subjects will occur within 28 days prior to the first dosing.&#xD;
&#xD;
      To assess the effect of multiple oral doses of edasalonexent on the single-dose&#xD;
      pharmacokinetics (PK) of midazolam (a cytochrome P450 [CYP]3A4 sensitive substrate) and of&#xD;
      deflazacort (a CYP3A4 moderate sensitive substrate) in healthy adult subjects.&#xD;
&#xD;
      Visit assessments include Clinical laboratory tests, Safety ECGs and Cardiodynamic ECGs.&#xD;
      Subjects will be housed on Day -3 of Period 1, until after the 24-hour blood draw and/or&#xD;
      study procedures are completed on Day 12 of Period 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2020</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of edasalonexent with midazolam and deflazacort</measure>
    <time_frame>12 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTc interval with edasalonexent</measure>
    <time_frame>12 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reported treatment-related adverse events</measure>
    <time_frame>12 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg midazolam on Day 1 and 36 mg deflazacort on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg edasalonexent TID on Day 1 to Day 11 with 2 mg midazolam on Day 10 and with 36 mg deflazacort on Day 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edasalonexent 2000 mg TID</intervention_name>
    <description>CAT-1004 capsules</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam 2 MG/ML</intervention_name>
    <description>2 mg/ml syrup</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deflazacort 36Mg Tab</intervention_name>
    <description>36 mg tablets</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, male or female (of non-childbearing potential), 18-55 years of age,&#xD;
             inclusive at Screening&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 at Screening&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history&#xD;
&#xD;
          -  Ability to swallow multiple capsules/tablets.&#xD;
&#xD;
          -  Ability to understand the study procedures, willing and able to comply with the&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant medical condition or disease&#xD;
&#xD;
          -  History or presence of hypersensitivity to edasalonexent or excipients based upon&#xD;
             known allergies to compounds of a similar class such as salicylates, fish oil,&#xD;
             eicosapentaenoic acid, or DHA&#xD;
&#xD;
          -  History or presence of hypersensitivity to midazolam, deflazacort, or related&#xD;
             compounds (e.g., steroids or their formulation including lactose).&#xD;
&#xD;
          -  Participation in another clinical study within 30 days prior to the first dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Donovan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer, Catabasis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion Clinical Research Unit</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deflazacort</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

